Aminosin Injection

Adult dosage

Adults are based on an amino acid dose of 0.8g per kg of body weight per day (equivalent to 15 mL of this medication). It is administered via central vein intravenous infusion, together with glucose or others that provide adequate calories through non-oral nutritional therapy.

Children's dosage

Infants are based on an amino acid dose of 2.2g per kg of body weight per day (equivalent to 40 mL of this medication). It is administered via central vein intravenous infusion, providing adequate calories through non-oral nutritional therapy.

This medication must be used under medical supervision. Patients with allergies to the ingredients of this medication or those with progressive liver disease, at risk of hepatic coma should not use this medication. Patients with severe renal dysfunction or hypernitrogenemia, congenital amino acid metabolism disorders, and patients with metabolic acidosis should also not receive this medication. Patients with heart failure or acute pulmonary failure, conditions that require excessive fluid supply, patients with oliguria or anuria, and patients who have had a myocardial infarction should avoid this medication. Patients with dehydration should adequately supply fluids and electrolytes to correct their status before cautious administration. Patients with hyponatremia or hypokalemia should ensure sufficient sodium and potassium supply and exercise caution. Patients with impaired liver or kidney function should adjust the dosage according to their condition and carefully monitor liver function and blood ammonia levels. Patients with pulmonary edema or heart failure should be administered while closely monitoring fluid status. For patients with congenital non-protein amino acid metabolism disorders and infants under 2 years old, the benefits and risks should be carefully evaluated before administration. This medication may cause anaphylaxis or hypersensitivity reactions in the immune system, and adverse hematologic reactions have also been reported. Metabolic complications such as nitrogenemia, hyperammonemia, liver dysfunction, cholestasis, and hepatic steatosis may occur during non-oral nutritional therapy. Inflammation, pain, erythema, etc., may occur at the infusion site, so care is required. Excessive addition of calcium and phosphates may pose a risk of forming calcium phosphate precipitates, so solutions and infusion sets should be regularly inspected. Frequent measurement of blood ammonia levels is necessary, and if hyperammonemia occurs, administration should be halted and the condition assessed. Serum electrolyte concentrations, blood sugar, fluid balance, acid-base balance, and kidney and liver functions should be regularly checked. This medication is important to administer alongside appropriate sources of energy, vitamins, trace elements, and electrolytes as part of non-oral nutrition. For adequate protein synthesis, it is mandatory to administer it along with a non-protein energy source such as concentrated glucose solution. When combined with glucose solution, hyperglycemia, diabetes, and hyperosmolar syndrome may occur, so blood and urine sugar levels should be monitored. With high-volume administration, attention must be given to electrolyte balance, and when using with other nutritional solutions, the possibility of peripheral venous administration should be determined based on osmotic concentration. Hyperosmolar solutions may irritate peripheral veins, so caution is required. Mixtures containing amino acids may promote acute folate deficiency, so folate should be administered daily. The safety of this medication has not been sufficiently studied in pregnant or breastfeeding women, and it should only be used when the therapeutic benefits outweigh the risks. The safety and efficacy in children have not been adequately established. The elderly may have reduced body functions, so the rate of administration should be slow and dosage adjusted. Overdosage or excessive infusion rates may lead to blood volume overload, electrolyte imbalance, acidosis, and nitrogenemia; in such cases, administration must be stopped immediately. This medication is sensitive to light, so it should be shielded when administered to children under 2 years old, and after mixing, it should be prepared under sterile conditions and used immediately. If the solution is discolored or cloudy, or if the packaging is damaged, it should not be used and should be stored at room temperature away from direct sunlight.

Serious side effects

Anaphylaxis/anaphylactoid reactions (urticaria, skin and gastrointestinal symptoms, shock, respiratory symptoms), pulmonary vascular precipitations, hyperammonemia, liver failure, jaundice due to elevated blood bilirubin, cirrhosis, liver fibrosis, acute skin adverse reactions (severe rashes, blisters, potential skin peeling, oral/eye mucosal pain), myocardial infarction and its history, edema, hypertension, severe edema and urination abnormalities, heart failure, pulmonary.

Mild side effects

Hypersensitivity reactions (fever, chills, hypotension, hypertension, joint pain, muscle pain, rash, pruritus, erythema, headache), phlebitis, pain, erythema, warmth, swelling, sclerosis, nitrogenemia, hyperammonemia, increased liver enzymes, cholecystitis, cholelithiasis, increased bilirubin, hepatic steatosis, cirrhosis, liver fibrosis, increased blood ammonia levels, hyperglycemia, diabetes, hyperosmolar syndrome, electrolyte imbalance, acidosis

This medication should be stored in a sealed container to protect from air exposure, and it is best to keep it in a cool place at a temperature between 1 degree and 25 degrees Celsius. This will help maintain the effectiveness of the medication for a longer period.

Appearance

A colorless or pale yellow transparent liquid in a colorless and transparent glass vial injection.

Package unit

200 milliliters/vial, 250 milliliters/vial